AMZN Research Update — August 28, 2026
Updated Thesis
Amazon is a high-quality global commerce, logistics, advertising, cloud-computing, and AI infrastructure platform whose Prime ecosystem, third-party marketplace liquidity, fulfillment density, retail-media data, and AWS switching costs create a durable multi-layered moat. Fundamentals remain strong, with 19.6% revenue growth and 244.9% earnings growth in the most recent quarter, 50.8% TTM gross margin, 12.1% TTM operating margin, 17.4% TTM net margin, and 30.5% ROE; AWS generated $16.6 billion of Q2 2026 operating income at a 39.4% margin. At $256.26, the shares trade at 20.37 times trailing earnings and 11.42 times EV/EBITDA, appear fair relative to their five-year valuation history, and offer 45.0% upside to the $371.58 fair-value estimate, although trailing earnings were materially inflated by Anthropic-related investment gains and cash generation is burdened by an approximately $220 billion 2026 capex program.
The investment grade as of this refresh is A- — high business quality. A-tier business, fair-tier valuation with 45.0% upside to $371.58 fair value.
Grade Change
In this research cycle, the investment grade for Amazon.com, Inc. moved from B to A-. A-tier business, fair-tier valuation with 45.0% upside to $371.58 fair value.
Key Metrics at a Glance
- Revenue growth: +19.6% year over year
- Net margin: 17.4%
- Fair value upside: +45.0% to our estimate of $372
Current price: $256.26
These figures reflect our most recent data pull and are one input into a multi-factor valuation framework.
Our 12–18 Month Outlook
Quality companies held over a multi-year horizon benefit from compounding fundamentals and the patience to ride through short-term volatility. Amazon.com, Inc. remains in our covered universe with a high-quality assessment. We update research when material data changes — earnings revisions, management shifts, or regime changes in valuation — not on every price fluctuation.
Long-term accumulation of quality businesses at fair or better prices is the core of the Patient Accumulator approach. Research updates like this one inform whether to add, hold, or wait for a better zone — not whether to react to short-term price moves.
[View full AMZN research →](/stocks/AMZN)